US Stock MarketDetailed Quotes

OCGN Ocugen

Watchlist
  • 0.9074
  • +0.0065+0.72%
Close Nov 22 16:00 ET
  • 0.9002
  • -0.0072-0.79%
Post 20:01 ET
264.34MMarket Cap-4775P/E (TTM)

About Ocugen Company

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Company Profile

SymbolOCGN
Company NameOcugen
Listing DateDec 3, 2014
Issue Price11.00
Founded2013
CEODr. Shankar Musunuri, M.B.A.,PhD
MarketNASDAQ
Employees65
Fiscal Year Ends12-31
Address11 Great Valley Parkway
CityMalvern
ProvincePennsylvania
CountryUnited States of America
Zip Code19355
Phone1-484-328-4701
Websitehttp://www.ocugen.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Shankar Musunuri, M.B.A.,PhD
  • Chairman of the Board and Chief Executive Officer
  • 7.66M
  • Ramesh Ramachandran
  • Principal Financial Officer and Chief Accounting Officer
  • --
  • Dr. Huma Qamar, M.D.,PhD
  • Chief Medical Officer
  • --
  • Arun Upadhyay, PhD
  • Chief Scientific Officer and Head, Research, Development, and Medical
  • --
  • Dr. Marna C. Whittington, PhD
  • Independent Director
  • 649.56K
  • Kirsten Castillo, M.B.A.
  • Independent Director
  • 348.18K
  • Dr. Prabhavathi Fernandes, PhD
  • Lead Independent Director
  • 357.60K
  • Dr. Junge Zhang, PhD
  • Independent Director
  • 335.56K
  • Uday B. Kompella, PhD
  • Independent Director
  • 341.82K
  • Michael Breininger, C.P.A.,M.B.A.
  • Corporate Controller
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data